Source: Eur Respir J 2006; 28: 1069-1072
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bush A.. Evidence-based medicines for children: important implications for new therapies at all ages. Eur Respir J 2006; 28: 1069-1072

Member's Comments

No comment yet.

Related content which might interest you: Evidence-based medicines for children: ethical aspects Source: Eur Respir J 2007; 29: 821-822 Year: 2007 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 Respiratory medicines for children: current evidence, unlicensed use and research priorities Source: Eur Respir J 2010; 35: 247-265 Year: 2010 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Current insights and potential benefits for effective teaching and learning in respiratory medicine Source: Breathe 2012; 9: 15-24 Year: 2012 How do the new guidelines work? Practical approach to the new guidelines for asthma diagnosis in children, discussion and Q&A Source: Virtual Congress 2021 – The ERS guidelines for the diagnosis of asthma in children aged 5-16 years Year: 2021 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 From guidelines to personalized treatment of children with asthma Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 In the era of personalized medicine, what are the current unmet needs in asthma? Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Recommended new therapies for severe asthma and the future Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017 The new WHO air quality guidelines: policy and clinical implications for children with respiratory diseases Source: Virtual Congress 2021 – The environment and climate change effects on lung health across the lifecourse Year: 2021 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021